Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer

Former President of Alcresta Therapeutics brings development, operational and strategic leadership experience as Synspira builds product pipeline Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 C... Biopharmaceuticals, Personnel Synspira Therapeutics, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news